Dermatomycosis;Micosis cutáneas

Medicina Clinica

Volumn 125, Issue 12, 2005, Pages

  Crespo Erchiga, Vicente ^a   Delgado Florencio, Vicente ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 (2,4 DIFLUOROPHENYL) 3 METHYL 2 (1H 1,2,4 TRIAZOL 1 YL) 4 [4 (TRIFLUOROMETHYL)BENZOYL]MORPHOLINE; 2 (2,4 DIFLUOROPHENYL) 6 HYDROXY 3 METHYL 2 (1H 1,2,4 TRIAZOL 1 YL) 4 [4 (TRIFLUOROMETHYL)BENZOYL]MORPHOLINE; ALLYLAMINE DERIVATIVE; ALUMINUM CHLORIDE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ASTRINGENT AGENT; BIFONAZOLE; BUTOCONAZOLE; CICLOPIROXOLAMINE; CLOTRIMAZOLE; DERMOSEPTIC; EBERCONAZOLE; ECONAZOLE; ECOTAM; FENTICONAZOLE; FLUSPORAN; FLUTRIMAZOLE; FUNCENAL; FUNGIDERMO; FUNGISIDIN; IMIDAZOLE DERIVATIVE; IODINE; ITRACONAZOLE; KETOCONAZOLE; KETOISDIN; MICETAL; MICOESPEC; MICONAZOLE; MICOTER; MOLDINA; MORPHOLINE DERIVATIVE; MYCOSPOR ONICOSET; NYSTATIN; PERMANGANATE POTASSIUM; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PROPYLENE GLYCOL; PYRITHIONE ZINC; PYRROLE DERIVATIVE; RAVUCONAZOLE; SALONGO; SELENIUM SULFIDE; SERTACONAZOLE; T 8581; TOLNAFTATE; TROSDERM; TROSID; TROSID UNAS; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHITFIELD OINTMENT;

ATOPIC DERMATITIS; CANDIDA; CLINICAL FEATURE; DERMATOLOGY; DERMATOMYCOSIS; DIARRHEA; EPIDERMOPHYTON; FOLLICULITIS; HUMAN; MALASSEZIA; MICROSPORUM; NAUSEA; PUSTULOSIS; REVIEW; SEBORRHEIC DERMATITIS; TINEA VERSICOLOR; TRICHOPHYTON; VOMITING;

EID: 27744575784     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079613     Document Type: Article

References (66)

1. Rippon JW. Dermatophytosis and dermatomycosis. En: Rippon JW, editor. Medical Mycology. The pathogenic fungi and actimomycetes. Philadelphia: W.B. Saunders; 1988. p. 169-275.
2. Martínez JA, Losa JE, Mensa J. Infecciones fúngicas en la asistencia primaria. Med Integral. 1997;29:36-54.
3. Hart R, Bell-Syer S, Crawford F, Toregerson D, Young P, Russell I. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ. 1999;319:79-82.
4. th ed. Oxford: Blackwell Scientific Publications; 1986. p. 885-986.
5. Goslen JB, Kobayashi GS. Enfermedades micóticas con compromiso cutáneo. En: Fitzpatrick TB, editor. Dermatología en medicina general. Panamericana; 1998.
6. Delgado V, Crespo V. Micosis cutáneas. Medicine (ed. esp.). 2002;8: 4805-15.
7. Crespo V, Vera A, Ojeda A, Crespo A. Epidemiología de las tiñas en España. Piel. 1999;1:175-85.
8. Pereiro-Miguens M, Pereiro E, Pereiro M Jr, Pereiro M, Toribio J. Incidencia de los dermatofitos en España desde. 1926 a 1994. Actas Dermosifiliogr. 1996;87:77-84.
9. Bordel MT, De Mariscal A, Torrero MJ, Miranda A, Vega J. Contribución al estudio epidemiológico de las dermatofitosis en el área este de Valladolid. Actas Dermosifiliogr. 2002;93:495-9.
10. Crespo V, Ojeda A, Vera A, Crespo A, Sánchez-Fajardo S. Aislamiento e identificación de Malassezia spp. En pitiriasis versicolor, dermatitis seborreica y piel sana. Rev Iberoam Micol. 1999;16:16S-21S.
11. Crespo V, Ojeda A, Vera A. Crespo A, Sánchez-Fajardo S. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol. 2000;143:799-803.
12. Crespo V, Delgado V. Malassezia species in skin diseases. Curr Opin Infect Dis. 2002;15:133-42.
13. Pontón J. Diagnóstico microbiológico de las micosis. Rev Iberoam Micol. 2002;19:25-9.
14. Crespo V, Casañas C, Ojeda A, Crespo A, Vera A, Casaño V, et al. Examen direct versus culture. Etude sur 1115 cas de dermatomycoses. J Mycol Med. 1999;9:154-7.
15. Crespo V, Ojeda A, Vera A. Crespo A, Sánchez-Fajardo S. Evaluation of a modified PAS stain procedure for direct mycological examination. Mikologia Lekarska. 1996;3:159-62.
16. Garzón R, Carballo M, Del Valle E, Cipitelli L. La importancia de la preparación del paciente en el examen micológico de laboratorio. Rev Iberoam Micol. 1998;15:307-8.
17. Alou L, Maestre JR, Moreno R. Consumo de antifúngicos de uso tópico en España. Rev Esp Quimioterap. 2001;14:340-4.
18. González C, Lecha V, Herrero C. Terapéutica antifúngica en dermatología. Piel. 1995;10:157-63.
19. Torres JM. Micosis que afectan a la piel y mucosas. Doyma; 1987. p. 137-8.
20. Carrillo-Muñoz AJ, Pemán J, Gobernado M. Nuevos antifúngicos. Presente y futuro. Rev Esp Quimioter. 1999;12:181-92.
21. Stiller MJ. Systemic drugs in the treatment of dermatophytoses. Int J Dermatol. 1993;32:16-21.
22. Hay RJ. Antifungal drugs in dermatology. Semin Dermatol. 1990;4:309-17.
23. Seehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999;12:40-79.
24. Brennan B, Leyden JJ. Overwie of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:3S-8S.
25. Phillips RM, Rosen T. Topical antifungal agents. En: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia: W.B. Saunders Co.; 2001. p. 497-523.
26. Ginarte M, Paredes C. Empleo de antiinfecciosos en patología cutánea. Tratamiento sistémico y tópico. Contraindicaciones. Criterios de respuesta. Efectos secundarios. Medicine (ed. esp.). 2002;8:4768-73.
27. Segurado A, Trasobares L, Suárez E. En: Medimecum, Guía de terapia farmacológica. Antimicóticos dermatológicos. Adis International; 2004.
28. Smith E. New topical agents for dermatophytosis. Cutis. 1976;17:54-8.
29. Smith E. Topical antifungical agents. Dermatol Clin. 1984;2:109-13.
30. Qadripur SA. Antimycotic therapy 2. Antimycotic chemotherapeutic agents: imidazole derivatives, tolciclate, haloprogin, ciclopiroxolamin. Fortschr Med. 1983;101:355-63.
31. Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin. 2003;21:481-9.
32. Bossche Van den H, Marichal H, Gorrens P, Geerts R, Brasseur C, Ruysschaert JM. Mode of action studies. Ann NY Acad Sci. 1988;144:191-207.
33. Font E, Freixes J, Julve J. Perfil del nuevo antimicótico tópico eberconazol. Rev Iberoam Micol. 1995;12:16-27.
34. Rubin AL, Bagheri B, Scher RK. Six nobel antimicotics. Am J Clin Dermatol. 2002;3:71-81.
35. Torres JM, Urrea A. Nuevos antifúngicos tópicos. Rev Esp Quimioter. 1992;5:343-8.
36. Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev. 1988;1:187-217.
37. Galimberti R, Belli L, Gatti JC. An open, multicentre assessment of the effectiveness of bifonazole in the treatment of pitiriasis versicolor. Pharmacotherapheutica. 1985;4:109-12.
38. Carrillo AJ. Antifúngicos tópicos en micosis cutáneas. Actualidad Dermatológica. 1997:361-73.
39. Bada JL. Tratamiento farmacológico de las micosis. En: Torres JM, editores. Micosis que afectan piel y mucosas. Barcelona: Doyma; 1989. p. 137-63.
40. Edgar B, Smith MD. Topical antifungical agents. Dermatol Clin. 1984;2: 109-13.
41. Tomas JM, Camprubí S, Merino S, Pares R, Llauradó X, Julve J. Inhibition of two imidazole antimycotics, eberconazole and clotrimazole, by different components of Candida albicans serotype B membrane protoplasts. Int J Antimicrob Agents. 1993;3:61-4.
42. Torres-Rodríguez JM, Mendez R, López-Jodra O, Morera Y, Espasa M, Jiménez T, et al. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrob Agents Chemother. 1999;43:1258-9.
43. Fernández-Torres B, Inza I, Guarro J. In vitro activities of the new antifungal drug eberconazole and three other topical agents against. 200 strains of dermatophytes. J Clin Microbiol. 2003;41:5209-11.
44. Torres-Rodríguez JM, Madrenys-Brunet N, Montsant L. Tratamiento tópico de la candidosis cutánea experimental del cobayo con eberconazol. Rev Iberoam Micol. 1999;16:43-5.
45. Fonseca E. Eficacia del eberconazol crema al 1% trente a clotrimazol al 1% en pacientes con micosis cutáneas. Piel. 2004;19:480-4.
46. Viayna C, Álvarez D, Domper N, Puerta L, Martínez D, López R. Effectiveness and security of eberconazol cream to 1% in comparison with miconazol cream to 2% in the treatment of dermatofitosis. Comunicación Congreso Europeo de Dermatología Mayo. 2004 (EADV).
47. Heel RC, Brogden RN, Speight TM, Carmine A, Morley PA, Avery GS. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 1978;16:177-201.
48. Sartani A, Cordaro CI, Panconesi E. A multicenter trial with a new imidazole derivative, fenticonazole, in superficial fungal skin infections. Curr Ther Res Clin Exp. 1988;43:1194-1203.
49. Leris E. Perfil de un Nuevo antimicótico tópico. Flutrimazol. Rev Iberoam Micol. 1995;12:116-7.
50. García J, Dronda MA, Merlos M, Forn J, Torres JM, Zapatero MI, et al. In vitro and in vivo studies with flutrimazole: a new imidazole derivative with antifungal activity. Arzneim Forsch Drug Res. 1992;42:836-40.
51. Velasco A, Roman C, Aragues M, Noguera X, Ventura C, Leris E. Comparison of the efficacy of 1% flutrimazole cream twice a day with 1% flutrimazole cream once a day for the treatment of superficial dermatophytoses. Rev Iberoam Micol. 2002;19:169-72.
52. Savin RC, Horwitz SN. Doble-blind comparison of 2% ketoconazole cream and placebo in the treatment of tenia versicolor. J Am Acad Dermatol. 1986;15:500-3.
53. Cox F, Stiller R, South D. Oral ketoconazole for dermatophyte infections. J Am Acad Dermatol. 1982;6:455-62.
54. Suschka S, Fladung B, Merk HF. Clinical comparison of the efficacy and tolerability of once daily Canesten with twice daily Nizoral (clotrimazole 1% cream vs. ketoconazole 2% cream) during a 28-day topical treatment of interdigital tinea pedis. Mycoses. 2002;45:91-6.
55. Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician. 2000;61:2703-10, 2713-24.
56. Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS. Miconazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 1975;9:406-23.
57. Polak A. Oxiconazole, a new imidazole derivative. Arzneim-Forsch. 1982;32:17-24.
58. Palacín C, Ortiz JA. Sertaconazol. Rev Iberoam Micol. 1995;12:84-5.
59. Carrillo AJ, Torres J. In vitro antifungal activity of sertaconazole, econazole and bifonazole against Candida sp. J Antimicrob Chemother. 1995;36:713-6.
60. Lozano R, García MT, Márquez M. Sertaconazol, aspectos farmacológicos y experiencia clínica de un nuevo antimicótico. Act Dermatol. 1991; 615-21.
61. Alomar C, Bassas S, Casas M, Crespo V, Ferrandiz C, Fonseca E, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneim-Forsch. 1992;42:767-73.
62. Brennan B, Layden J. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:3S-8S.
63. Baran R, Hay R, Haneke E, Tosti A. Onicomicosis, aproximación actual al diagnóstico y tratamiento. Londres: Martin Dunitz; 2000.
64. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacological properties, and therapeutic potential in superficial mycoses. Drugs. 1992;43:259-84.
65. Gupta AK. Systemic antifungal agents. En: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia. WB Saunders Company; 2001. p. 55-84.
66. Crawford F, Hart R, Bell-Syer S, Torgerson D, Young P, Russell I. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane review Issue 3(CD001434). The Cochrane Library; 2004. p. 1-107